Any current/future new fundraising through debt or equity?

Beta Drugs Limited has recently completed a fundraising of INR117 crores from marquee investors, including HealthQuad, Tanas Capital, and a generational capital fund. The funds raised are primarily earmarked for future growth initiatives: state-of-the-art R&D facilities (formulation and API), establishment of an intermediate plant, and venturing into recombinant proteins. There was no indication of any additional current or future fundraising through debt or equity during this conference call. The company is focusing on using internal accruals for regular capex around INR10-12 crores in FY26.

Any current/future capex/capital investment/strategic investment?

Planned capex for FY26 excluding new projects: INR 10-12 crores from internal accruals. Fundraise of INR 117 crores for strategic investments: - Establishing a state-of-the-art combined R&D facility (formulation + API) with INR 10-15 crores capex. - Setting up an intermediate plant with an investment of INR 15-20 crores to reduce dependence on China and support API production. - Future venture into recombinant proteins and biosimilars. R&D expense expected to rise from current 2-3% to 4-5% post new facility. Expansion in intermediate production aims to boost margins by 10-15% and cater i

Future growth expectations in sales/revenue/volumes?

Overall company growth targeted at 25% to 30% annually for the coming years. Export business expected to grow around 50% annually over the next 3-4 years, with focus on gaining registrations and entering EU and US markets. Domestic cytotoxic market expected to grow at a CAGR of 15-20%, reaching about INR 4,000-5,000 crores by 2028-2030. CDMO business to show steady growth with increasing sales in the second half of FY25; current first half sales around INR 72.7 crores. Derma segment to double revenue next financial year, reaching INR 26-30 crores with new product launches and expanded

Future growth expectations in earnings/operating earnings/profits/EPS?

Beta Drugs expects total company growth at 25%-30% over the next few years, with exports growing even faster. Export business is projected to grow around 50% annually for the next 3-4 years, aided by new registrations and dossier filings. API business is a key focus with plans for DMF filings and entry into regulated markets; currently exports in API are negligible but expected to grow. CDMO business sales showed 2%-5% growth H1 FY25, with expectations of steady and better sales in the next half. Derma segment aims to double sales to around INR26-30 crores next financial year with prod

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Beta Drugs Limited. However, management indicates a strong pipeline with plans to launch 5 new molecules and NDDS by next year. The company is experiencing significant growth in exports with a 141% increase, supported by new registrations and dossier filings. CDMO business growth is steady with all CDMO partners retained and expected sales to improve in the second half. Intermediate manufacturing facility investment of INR15-20 crores aims to boost internal API production, potentially increasing

Beta Drugs LtdQ2 FY25Pharmaceuticals & Biotechnology

Beta Drugs Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,849.7P/E: 45.0Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Overall company growth targeted at 25% to 30% annually for the coming years.
Export business expected to grow around 50% annually over the next 3-4 years, with focus on gaining registrations and entering EU and US markets.
Domestic cytotoxic market expected to grow at a CAGR of 15-20%, reaching about INR 4,000-5,000 crores by 2028-2030.
CDMO business to show steady growth with increasing sales in the second half of FY25; current first half sales around INR 72.7 crores.
Derma segment to double revenue next financial year, reaching INR 26-30 crores with new product launches and expanded prescriber network.
Intermediate production facility will boost internal API margins by 10-15%.
R&D focused on launching 20-25 products and developing new NDDS and biosimilar molecules over the next 2-3 years.

Margin guidance

Category 3

Beta Drugs expects total company growth at 25%-30% over the next few years, with exports growing even faster.
Export business is projected to grow around 50% annually for the next 3-4 years, aided by new registrations and dossier filings.
API business is a key focus with plans for DMF filings and entry into regulated markets; currently exports in API are negligible but expected to grow.
CDMO business sales showed 2%-5% growth H1 FY25, with expectations of steady and better sales in the next half.
Derma segment aims to double sales to around INR26-30 crores next financial year with product launches and new prescriber additions.
EBITDA margins expected to be around 22%-26% depending on segment; export margin is around 23%-26%.
Intermediate plant investment (~INR15-20 crores) to boost margins by 10%-15%.
Fundraise (~INR117 crores) targeted at R&D, intermediate facility, and recombinant proteins to drive future earnings growth.

See what Beta Drugs Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Beta Drugs Limited has recently completed a fundraising of INR117 crores from marquee investors, including HealthQuad, Tanas Capital, and a generational capital fund.
The funds raised are primarily earmarked for future growth initiatives: state-of-the-art R&D facilities (formulation and API), establishment of an intermediate plant, and venturing into recombinant proteins.
There was no indication of any additional current or future fundraising through debt or equity during this conference call.
The company is focusing on using internal accruals for regular capex around INR10-12 crores in FY26.
No new fundraising beyond the mentioned INR117 crores was discussed.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Beta Drugs Limited.
However, management indicates a strong pipeline with plans to launch 5 new molecules and NDDS by next year.
The company is experiencing significant growth in exports with a 141% increase, supported by new registrations and dossier filings.
CDMO business growth is steady with all CDMO partners retained and expected sales to improve in the second half.
Intermediate manufacturing facility investment of INR15-20 crores aims to boost internal API production, potentially increasing margins by 10-15%.
Expanding regulatory capabilities and approvals (EU-GMP, COFEPRIS, ZAZIBONA) indicate a growing ability to secure international contracts/orders.
Overall, while exact order book numbers are not stated, the company projects strong demand and growth across multiple verticals driven by regulatory registrations and new product launches.

See what Beta Drugs Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Planned capex for FY26 excluding new projects: INR 10-12 crores from internal accruals.
Fundraise of INR 117 crores for strategic investments:
- Establishing a state-of-the-art combined R&D facility (formulation + API) with INR 10-15 crores capex.
- Setting up an intermediate plant with an investment of INR 15-20 crores to reduce dependence on China and support API production.
- Future venture into recombinant proteins and biosimilars.
R&D expense expected to rise from current 2-3% to 4-5% post new facility.
Expansion in intermediate production aims to boost margins by 10-15% and cater initially to internal API requirements.
Plans for EU-GMP and Mexico COFEPRIS audits to enable regulated market entry.

Track Beta Drugs Ltd — get its next earnings analysis in your feed

How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisBeta Drugs Ltd

Rev 2Mar 3

See where Beta Drugs Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Beta Drugs Ltd rank in Pharmaceuticals & Biotechnology?

Compare Beta Drugs Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Beta Drugs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →